全國(guó)服務(wù)咨詢熱線：
18438616290
<b id="grzca"><menuitem id="grzca"></menuitem></b>
18438616290
簡(jiǎn)要描述：Carglumic Acid 1188-38-1Carglumic acid is an orphan drug used for the treatment of hyperammonaemia in patients with N-acetylglutamate synthase deficiency.
產(chǎn)品型號(hào)：abs47027285廠商性質(zhì)：生產(chǎn)廠家更新時(shí)間：2025-12-04訪 問 量：755產(chǎn)品分類
Product Category詳細(xì)介紹
| 品牌 | absin | CAS | 1188-38-1 |
|---|---|---|---|
| 分子式 | C6H10N2O5 | 純度 | ＞98% |
| 分子量 | 190.15 | 貨號(hào) | abs47027285 |
| 規(guī)格 | 5mg | 供貨周期 | 現(xiàn)貨 |
| 主要用途 | used for the treatment of hyperammonaemi | 應(yīng)用領(lǐng)域 | 化工,生物產(chǎn)業(yè),農(nóng)林牧漁,制藥/生物制藥,綜合 |
Carglumic Acid 1188-38-1
| 產(chǎn)品描述 | |
| 描述 | Carglumic acid is an orphan drug used for the treatment of hyperammonaemia in patients with N-acetylglutamate synthase deficiency. This rare genetic disorder results in elevated blood levels of ammonia, which can eventually cross the blood-brain barrier and cause neurologic problems, cerebral edema, coma, and death. Carglumic acid was approved by the U.S. Food and Drug Administration (FDA) on 18 March 2010. |
| 純度 | ＞98% |
| 儲(chǔ)存/保存方法 | Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution. |
| 基本信息 | |
| 別名 | 卡谷氨suan；卡哥魯酸；N-氨基甲酰-L-谷氨suan；N-Carbamyl-L-glutamic acid |
| 可溶性/溶解性 | DMSO ：38 mg/mL (199.84 mM) Water ：3 mg/mL (15.78 mM; Need ultrasonic and warming) |
| 生物活性 | |
| 靶點(diǎn) | CPS1 |
| In vitro(體外研究) | Carglumic acid suppresses cell viability in the pancreatic ductal adenocarcinoma cell lines, triple-negative breast cancer cell lines, hepatoma cell lines, and human non-small cell lung carcinoma cell lines in a dose-dependent manner. The 50% inhibitory concentration (IC50) of Carglumic acid against those cell lines is between 5 and 7.5 mM. The results show that Carglumic acid does not induce complete cell cycle arrest. Instead, there are more sub-G1 cells among Carglumic acid-treated AsPC1 and MDA-MB-231 cells than among untreated cells. In AsPC1 and HPDE-E6E7 cells, the IC50s of Carglumic acid are 5 mM and over 10 mM, respectively . In MDA-MB-231 and MCF-12A cells, the IC50s of Carglumic acid are 5 mM and 6 mM, respectively. |
| In vivo(體內(nèi)研究) | The results show that Carglumic acid, but not the vehicle control, markedly inhibits tumor growth. In the orthotopic pancreatic cancer model, tumor growth inhibition by Carglumic acid on day 21 is 80% (P<0.01). In the orthotopic triple-negative breast cancer model, tumor growth inhibition by Carglumic acid on day 20 is 82% (P<0.01). These results indicate that Carglumic acid suppresses tumor growth in pancreatic cancer and triple-negative breast cancer. On day 20, mean tumor growth inhibition in orally and intravenously treated mice is 55% and 93%, respectively, relative to untreated mice (P<0.01). |
| 參考文獻(xiàn) | |
| 參考文獻(xiàn) |
|
| 研究領(lǐng)域 | |
| 研究領(lǐng)域 | MetabolismPathways and ProcessesMetabolic signaling pathwaysAmino acid metabolism MetabolismPathways and ProcessesMitochondrial MetabolismMitochondrial markers Signal TransductionMetabolismAmino Acids Signal TransductionMetabolismMitochondrial Tags & Cell MarkersSubcellular MarkersOrganellesMitochondria Drug DiscoverySmall Molecule DrugLead Compound Discovery |
產(chǎn)品咨詢
地址：上海市浦東新區(qū)新浩路58號(hào)申江科創(chuàng)園18棟
郵箱：
傳真：